EXDENSUR

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

AsthmaChronic Obstructive Pulmonary DiseaseHypereosinophilic SyndromeAllergic Bronchopulmonary AspergillosisPulmonary Disease, Chronic ObstructiveNasal Polyps

175 competitors in Asthma

#DrugCompanyPhaseTrials

1

EXDENSUR

GGlaxo Dba Glaxosmithkline

Approved

32

Celexa

AbbVie

Preclinical

13

Arcoxia

Novartis

Preclinical

—4

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

15

DUPIXENT

Regeneron

Preclinical

16

Paracetamol

GSK

Preclinical

17

Blood Withdrawn

Emergent BioSolutions

Preclinical

18

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

19

Lexapro

SShirley Ryan AbilityLab

Preclinical

110

Biological Drug

UUniversitaire Ziekenhuizen KU Leuven

Preclinical

1Show 15 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Asthma3 trials

A Phase 3, Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Depemokimab (GSK3511294) Administered Subcutaneously as Add on Maintenance Treatment of Asthma With Type 2 Inflammation Characterised by an Eosinophilic Phenotype in Participants Aged 6 to 11 Years Old

Recruiting·GSK·Phase 3·NCT07671001·34 enrolled

The MODIFY Study: A Phase 3b/4 Randomized, Double-blind, Placebo-controlled, Multi-centre Study Evaluating the Impact of Early Intervention With Depemokimab on Exacerbation Rate, Clinical Remission, Lung Function Decline, and Safety in Adults and Adolescents With at Risk Type 2 Asthma, Conducted up to 156 Weeks

Recruiting·GSK·Phase 3·NCT07456033·456 enrolled

The IMAGINE Study: A Phase 3b Open Label, Single Arm Study to Assess the Effect of Depemokimab on Airway Structure and Function in Asthma With Type 2 Inflammation Characterized by an Eosinophilic Phenotype Utilizing Quantitative High-resolution CT and Bronchoscopic Airway Sampling in a Sub Study

Recruiting·GSK·Phase 3·NCT06979323·150 enrolled

Chronic Rhinosinusitis With Nasal Polyps2 trials

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

Completed·GSK·Phase 3·NCT05274750·276 enrolled

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)

Completed·GSK·Phase 3·NCT05281523·264 enrolled

Chronic Obstructive Pulmonary Disease2 trials

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

Recruiting·GSK·Phase 3·NCT06961214·960 enrolled

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

Recruiting·GSK·Phase 3·NCT06959095·981 enrolled

Adult1 trial

A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants

Completed·GSK·Phase 1·NCT05602025·140 enrolled

Allergic Bronchopulmonary Aspergillosis1 trial

Effectiveness and Safety of Depemokimab in Allergic Bronchopulmonary Aspergillosis (ABPA) With Severe Eosinophilic Asthma(SEA): a Prospective Study of Real-world Experience

Not yet recruiting·QQianfoshan Hospital·Preclinical·NCT07828327·10 enrolled

4 more indications

Nasal Polyps1 trial

A Phase IV, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of 100 mg SC Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Are Inadequately Controlled With Standard Treatment

Recruiting·GSK·Approved·NCT07701967·28 enrolled

Hypereosinophilic syndrome1 trial

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES)

Recruiting·GSK·Phase 3·NCT05334368·109 enrolled

Pulmonary Disease, Chronic Obstructive1 trial

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study of the Efficacy and Safety of Early Depemokimab Initiation as add-on Treatment in COPD Patients With Type 2 Inflammation

Recruiting·GSK·Phase 3·NCT07177339·1,196 enrolled

Eosinophilic Granulomatosis With Polyangiitis1 trial

A 52-week, Randomized, Double-blind, Double-dummy, Parallel-group, Multi-centre, Non-inferiority Study to Investigate the Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Receiving Standard of Care (SoC) Therapy

Active, not recruiting·GSK·Phase 3·NCT05263934·163 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Related News